A randomized trial evaluating liraglutide for obesity in children 6 to <12 years of age was published on January 1, 2025, in the New England Journal of Medicine. The study, known as SCALE KIDS, investigated the drug's effectiveness in lowering weight in this pediatric population.
Background
Liraglutide is a medication studied for various conditions, including obesity. This particular trial focused on its use in children aged 6 to <12 years with obesity.
Trial design
The published research, titled "Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial," was designed to assess the effectiveness of liraglutide. The study, referred to as SCALE KIDS, specifically aimed to evaluate how well the medication performed in lowering weight among children aged 6 to <12 years who have obesity.
What this means
The publication of this randomized trial on liraglutide for obesity in children 6 to <12 years of age makes the full study findings available to the medical community. While the provided data confirms the study's focus on evaluating weight reduction, specific efficacy or safety outcomes are not detailed in this summary. Clinicians and researchers can now access the full report in the New England Journal of Medicine to review the detailed results and their implications for pediatric obesity management.
Source
This information is based on a publication in the New England Journal of Medicine, indexed by PubMed, on January 1, 2025. The article, titled "Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial," is accessible via pubmed.ncbi.nlm.nih.gov.